Page last updated: 2024-12-07
idremcinal
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Idremcinal: a motilin receptor agonist in human gastric antrum; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 84019 |
CHEMBL ID | 2103968 |
SCHEMBL ID | 21931814 |
MeSH ID | M0238165 |
Synonyms (27)
Synonym |
---|
idremcinal |
idremcinal (usan/inn) |
110480-13-2 |
D04497 |
(2r,3r,4s,5r,8r,9s,10s,11r,12r)-5-ethyl-3,4-dihydroxy-9-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3r,4s,6r)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec |
8,9-didehydro-n-demethyl-9-deoxo-6-deoxy-6,9-epoxy-n-isopropylerythromycin |
unii-0m6189xxjn |
em574 |
em-574 |
8,9-didehydro-n-demethyl-9-deoxo-6-deoxy-6,9-epoxy-n-(1-methylethyl)erthromycin |
idremcinal [usan:inn] |
8,9-didehydro-n-demethyl-9-deoxo-6-deoxy-6,9-epoxy-n-(1-methylethyl)erythromycin |
0m6189xxjn , |
CHEMBL2103968 |
AKOS025294079 |
idremcinal [usan] |
idremcinal [inn] |
HB3887 |
em 574 |
J-002432 |
DTXSID10891360 |
SCHEMBL21931814 |
(2r,3r,4s,5r,8r,9s,10s,11r,12r)-5-ethyl-3,4-dihydroxy-11-(((2s,3r,4s,6r)-3-hydroxy-4-(isopropyl(methyl)amino)-6-methyltetrahydro-2h-pyran-2-yl)oxy)-9-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-2,4,8,10,12,14-hexamethyl-6 |
gtpl11813 |
Q27236956 |
HY-105263 |
CS-0025533 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Thirty healthy volunteers received one of five oral doses of EM574 (5, 10, 20, 30 mg and placebo) in a randomized, double-blind, five-period, cross-over design; each dosing period was separated by 1-wk washout." | ( Dose-related effects of N-demethyl-N-isopropyl-8, 9-anhydroerythromycin A 6,9-hemiacetal on gastric emptying of solids in healthy human volunteers. Burton, DD; Camilleri, M; Choi, MG; Edmonds, A; Johnson, S, 1998) | 0.3 |
" The cumulative amount (A(app)) of drug appearing in the systemic circulation was calculated by deconvolution, where the input response was the plasma concentration-time profile during intestinal perfusion and the unit impulse response was the mean profile following intravenous bolus dosing to sham-operated rabbits in a separate experiment." | ( Intestinal absorption and presystemic elimination of the prokinetic agent, EM574, in the rabbit. Cartier, LL; Gan, G; Huang, Y; Sawchuk, RJ; Yang, Z, 2002) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (17)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 11 (64.71) | 18.2507 |
2000's | 6 (35.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.24
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.24) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (5.56%) | 5.53% |
Reviews | 1 (5.56%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |